Pharma article – November 9, 2026
Each person with opioid dependence who starts or stays in treatment for a year is associated with an estimated GBP 140,876 in lower societal costs in the UK. That is the finding of a new study by Lund-based Camurus and the Swedish Institute for Health Economics (IHE).
Pharma article – November 9, 2026
Cantargia has announced IL-17 as the second target for the bispecific antibody CAN14.
Pharma Business – November 9, 2026
Xspray Pharma says the US FDA has begun an inspection at NerPharMa, the contract manufacturer whose cGMP status must be cleared before the agency can approve the company’s cancer drugs Dasynoc and Nilopki. Xspray has also resolved on a rights issue of about SEK 90 million, which can be increased by about SEK 72 million through an over-allotment issue.
Clinical Trials – November 9, 2026
Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.
Clinical Trials – November 5, 2026
Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.
In a new job – November 5, 2026
Sarah Fredriksson, former CEO of Aqilion and founder of Genovis, took over as CEO of AAX Biotech on November 1, 2026. Co-founder Daniel X Johansson remains Chief Scientific Officer (CSO) and board member.
Clinical Trials – November 9, 2026
Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.
Clinical Trials – November 5, 2026
Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.
Clinical Trials – November 4, 2026
Uppsala-based Abera Bioscience has received approval from the Dutch Central Committee on Research Involving Human Subjects (CCMO) to start a Phase I trial of its nasal pneumococcal vaccine candidate Ab-01.12. The approval marks the company’s move from preclinical to clinical development.
Clinical Trials – November 3, 2026
Camurus has dosed the first patient in LUNAR-2, a randomized, double-blind, placebo-controlled Phase IIb study of CAM2056, its monthly semaglutide depot, in people with overweight or obesity.
Clinical Trials – November 2, 2026
Lytix Biopharma’s Phase II NeoLIPA study, which gives ruxotemitide with pembrolizumab before surgery in patients with resectable melanoma, has met its primary endpoint of pathological complete response (pCR).
Clinical Trials – October 30, 2026
Umecrine Cognition’s golexanolone did not significantly improve cognition compared with placebo in a Phase 1b/2a trial in patients with primary biliary cholangitis (PBC). Majority owner KDventures is writing down its holding in the company to zero.
PharmaRelations
Do you have a strong network in the Finnish Life Science industry and enjoy turning relationships into business opportunities?
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
In a new job – November 3, 2026
Mercodia has appointed Helena Åsbrink as interim CEO, effective November 2, 2026.
In a new job – November 3, 2026
Anders Andersson has been appointed CEO of Mölnlycke Health Care and Fredrik Wallefors President Surgical, both effective January 1, 2027.
In a new job – November 2, 2026
The Nomination Committee of Swedish Orphan Biovitrum (Sobi) proposes that Börje Ekholm is elected as new Board member and Chair of the Board at the 2027 Annual General Meeting.
Careers article – October 20, 2026
Stamina, mentors, passion, and a life outside the lab. When Nordic Life Science profiled five leaders from across the region’s life science industry, from investors to a startup founder to two of its leading scientists, each shared advice for people starting out. Their answers had a lot in common.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Acquisition – November 5, 2026
US-based ANI Pharmaceuticals has made a public cash offer for Egetis Therapeutics worth about SEK 5.3 billion. The Egetis board unanimously recommends that shareholders accept.
Pharma Business – November 4, 2026
Boule Diagnostics will stop developing, manufacturing and selling hematology instruments, and will focus instead on consumables, service and its US contract manufacturing business. To fund the transition, the company plans a fully secured rights issue of about SEK 93 million.
Pharma Business – November 4, 2026
Novo has raised its full-year 2026 outlook after a stronger-than-expected third quarter. Adjusted sales and adjusted operating profit are now both expected to change by −2% to +2% at constant exchange rates, up from 0% to −6% previously, driven by higher expectations for GLP-1 sales. It is the company’s third outlook upgrade this year.
Agreement – November 4, 2026
Finnish Nightingale Health has signed two proteomics service agreements worth USD 1 million each, one with Alzheimer’s Research UK and one with medical research organization LifeArc. Both cover analysis of UK Biobank samples for research into neurodegenerative diseases.
Business Award – October 30, 2026
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award.
MedTech Business – October 29, 2026
Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).
Biotech Business – November 3, 2026
Trondheim-based Vitroscope has raised USD 7 million, made up of a USD 5 million seed round co-led by Cerberus Ventures and YZR Capital and USD 2 million in non-dilutive funding from the Research Council of Norway.
Biotech Business – November 3, 2026
Rayca Precision, which operates in Helsinki and London, has partnered with Dutch TechBio company QurieGen to offer pharma and biotech R&D teams a joint workflow that connects the discovery of new drug targets with the design and testing of drug candidates.
Biotech Business – November 2, 2026
Swedish biotech BioInvent plans a rights issue of approximately SEK 430 million to fund development of its anti-TNFR2 antibody BI-1808 and its other priority programs. The company also proposes to cut up to 20 positions.
Funding – October 30, 2026
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily.
Funding – October 27, 2026
Researchers at Karolinska Institutet have been granted a total of SEK 59 million from the Swedish research council Formas for two new research programs on how climate change affects human health.
Science Award – October 27, 2026
Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.
This site uses cookies
